



Xencor, Inc.  
Investor Relations Department  
111 West Lemon Avenue  
Monrovia, CA 91016  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: XNCR**


Last Trade:	22.50
Trade Time:	4:00 PM ET Jan 12, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	18.55 - 28.64
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Since Xencor's founding in 1997, investors have been drawn to our remarkable scientific capabilities around monoclonal antibodies and solid intellectual property which serve as the engine behind our drug development programs. Currently, 11 candidates that have been engineered with Xencor's XmAb® technology are in clinical development by us or with partners. Xencor's internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1a development fo... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Jan 5, 2018*  
[Xencor Announces 2018 Priorities and Expected Milestones](#)
- Dec 19, 2017*  
[Xencor Appoints Richard Ranieri to Board of Directors](#)
- Dec 5, 2017*  
[Xencor Receives Milestone Payment from Amgen](#)
- Nov 8, 2017*  
[Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer \(SITC\) 2017 Annual Meeting](#)
- Nov 7, 2017*  
[Xencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 1, 2017*  
[Annual Report \(10-K\)](#)
- May 1, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 7, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*  
[Quarterly Report \(10-Q\)](#)